Age, impaired fasting glucose, and cirrhosis predicted mortality at mean 7.6 years for nonalcoholic fatty liver disease

January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p22
Academic Journal
The article focuses on a clinical study to determine the natural history of nonalcoholic fatty liver disease (NAFLD) in community-based patients. 435 patients diagnosed with NAFLD, fatty liver, hepatic steatosis, steatohepatitis, or cryptogenic cirrhosis confirmed by ultrasonography, computed tomography, or magnetic resonance imaging, between 1 January 1980 and January 1, 2000. Liver-related death occurred in 7 patients and was the third leading cause of death after cancer and ischemic heart disease, compared with the thirteenth cause of death in the general population. In patients with nonalcoholic fatty liver disease, mortality was higher than that of the general population. Age, impaired fasting glucose, and cirrhosis at baseline predicted higher mortality.


Related Articles

  • Cardiovascular disease in patients with non-alcoholic fatty liver disease. Kantartzis, Konstantinos; Stefan, Norbert // Annals of Gastroenterology;Jul-Sep2012, Vol. 25 Issue 3, p276 

    As it affects almost every third individual in the general population in the Western world, non-alcoholic fatty liver disease (NAFLD) represents the most common cause of chronic liver disease and the most common cause of liver transplantation. Recently, NAFLD has gained much attention in the...

  • Esteatose hepática na obesidade infantil: investigação por imagem. Soder, Ricardo Bernardi; Baldisserotto, Matteo // Scientia Medica;Dec2009, Vol. 19 Issue 4, p202 

    Aims: To review hepatic steatosis in obese children, with emphasis on the imaging investigation. Source of data: Literature review about the topic, using the PubMed, SciELO and LILACS databases. Summary of the findings: Among pediatric population, hepatic steatosis has a 2.6% world prevalence...

  • Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease. Chiba, Mayumi; Sasaki, Motoko; Kitamura, Seiko; Ikeda, Hiroko; Sato, Yasunori; Nakanuma, Yasuni // Journal of Clinical Pathology;Jun2011, Vol. 64 Issue 6, p564 

    Aims Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of pathological conditions, ranging from simple steatosis to hepatic fibrosis with progression to cirrhosis. While activated hepatic stellate cells (HSC) are known to be involved in intralobular, perisinuosidal fibrosis, the...

  • Enfermedad hepática por depósito graso en pacientes no alcohólicos y no obesos: reflexiones a propósito de un caso. Aguado, I. Carabaño; Otones, L. Llorente; Vega, V. M. Suárez // Acta Pediátrica Española;mar2011, Vol. 69 Issue 3, p242 

    Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease in children and adolescents in some countries, as the United States of America. This fact may be due to a two-fold rise increase in rates of obesity in the last twenty years. The possible progress to...

  • The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Hartmann, Phillipp; Wei-Chung Chen; Schnabl, Bernd // Frontiers in Physiology;Sep2012, Vol. 3, preceding p1 

    Alcoholic liver disease (ALD) encompasses hepatic steatosis, which may progress to alcoholic hepatitis, fibrosis, and cirrhosis. It remains a leading cause of morbidity and mortality in the US and worldwide. The severity of liver disease correlates with plasma levels of bacterial products in...

  • Liver fibrogenesis in non-alcoholic steatohepatitis. Zhaolian Bian; Xiong Ma // Frontiers in Physiology;Jul2012, Vol. 3, p1 

    Non-alcoholic fatty liver disease (NAFLD) is emerging as one of the most common chronic liver diseases in developed western countries. Non-alcoholic steatohepatitis (NASH) is the most severe form of NAFLD, and can progress to more severe forms of liver disease, including fibrosis, cirrhosis, and...

  • Obesity and diabetes epidemics spur increase in nonalcoholic steatohepatitis.  // Biomedical Market Newsletter;12/14/2011, Vol. 21, p1 

    The article focuses on a research according to which post-transplantation survival for nonalcoholic steatohepatitis (NASH) patients is excellent with one-year survival rates near 88 percent. NASH occurs when fat builds up in the liver which damages the liver and leads to cirrhosis. The research...

  • Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization. Patidar, Kavish R; Sterling, Richard K; Sanyal, Arun J; Siddiqui, Mohammad S; Matherly, Scott C; Stravitz, R Todd; Puri, Puneet; Luketic, Velimir A; Fuchs, Michael; White, Melanie B; Noble, Nicole A; Unser, Ariel B; Gilles, HoChong; Heuman, Douglas M; Bajaj, Jasmohan S; Thacker, Leroy R; Wade, James B // American Journal of Gastroenterology;Nov2014, Vol. 109 Issue 11, p1757 

    OBJECTIVES:Despite the high prevalence of covert hepatic encephalopathy (CHE) in cirrhotics without previous overt HE (OHE), its independent impact on predicting clinically relevant outcomes is unclear. The aim of this study was to define the impact of CHE on time to OHE, hospitalization, and...

  • Obeticholic acid: expanding the therapeutic landscape of NASH. Arrese, Marco; Cabrera, Daniel; Barrera, Francisco // Annals of Hepatology: Official Journal of the Mexican Associatio;May/Jun2015, Vol. 14 Issue 3, p430 

    The article focuses on the therapeutic effect of obeticholic acid (OA) to Non-Alcoholic Steatohepatitis (NASH). It mentions that NASH is the chronic form of non-alcoholic fatty liver disease (NAFLD) and one of the common causes of cirrhosis around the world. It also talks about a study that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics